Saxenda (Liraglutide) FDA approval: 2014 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Also available as: Victoza (lower dose, approved for Type 2 diabetes) Ozempic (Semaglutide) FDA approval: 2017 for Type 2 diabetes Indicated population: Adults with Type 2 diabetes as adjunct to diet and exercise Not approved for: Weight loss (though commonly prescribed off-label) Wegovy (Semaglutide) FDA approval: 2021 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Adolescents aged 12+ with obesity Same medication as Ozempic: Different dosing and FDA indication Practical Implications The regulatory distinctions matter for: Insurance coverage: Medications are often covered only for their approved indications
Despite lacking the exendin 2029 sequence RLFIEWLKNG, GLP-1 and liraglutide exhibit analgesic effects, potentially through direct interactions with the TRPV1 receptor
We encourage balanced, sustainable eating habits
At the time of screening, the patients will undergo examinations to assure that all inclusion criteria and none of the exclusion criteria are met (Table 1)
USP General Chapter Bacterial Endotoxins Test: endotoxin limits for parenteral drugs
Metformin inhibits adenosine 5-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons
